Pricing Log in Create free account
Sunday 11 October 2026 Export all PFE data to Excel Powerpack

Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

28.28 0.46 +1.65%
Market cap
$158.6B
P/E
37.2×
Fwd P/E
12.2×
Dividend yield
6.08%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Pfizer Inc. 10-Q filed Aug 4, 2026

Fiscal Q2 2026 · Period ended Jun 28, 2026 · Filed · accepted 7:04 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 5, 2026: 37 added · 7 removed · 50 modified; 4 with only figures updated; 2 moved without change

  1. Added · Restructuring Programs

    Realigning Our Cost Base Program––In the third quarter of 2026, we announced $1.0 billion of additional anticipated net cost savings associated with this program driven by further productivity enhancements from technology and simplification efforts across our commercial, R&D and enabling functions. These additional net savings are expected to further reduce costs in SI&A and be realized from 2027 through 2029. We expect one-time costs to achieve the additional savings to be incurred through 2029 and to total approximately $2.0 billion.

93 more changes in this Item, word by word, in Powerpack.

Powerpack